SCHEMBL15020541

SCHEMBL15020541

COCc1nn2c(-c3ccc(Cl)cc3)cc(N3CCCC3CO)nc2c1-c1ccc(OC)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PLAT P00750 1/20 0.41
▸ KCNH2 Q12809 1/20 0.39
▸ FPR2 P25090 1/20 0.37
▸ SCN9A Q15858 1/20 0.37
▸ ADORA3 P0DMS8 1/20 0.37
▸ ADORA2A P29274 1/20 0.37
▸ ADORA1 P30542 1/20 0.37
▸ MAPT P10636 2/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ SPHK2 Q9NRA0 1/20 0.36
▸ ACVR1 Q04771 1/20 0.36
▸ TRPV1 Q8NER1 1/20 0.36
▸ SRC P12931 2/20 0.36
▸ CRHR1 P34998 1/20 0.35
▸ CDK1 P06493 2/20 0.35
▸ TRPV6 Q9H1D0 1/20 0.35
▸ SPHK1 Q9NYA1 2/20 0.34
▸ EGLN2 Q96KS0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15020540 1.00 PLAT (0.41) PLATKCNH2FPR2SCN9AADORA3
SCHEMBL15020996 0.92 PLAT (0.41) PLATKCNH2FPR2SCN9AADORA3
SCHEMBL15021000 0.92 PLAT (0.41) PLATKCNH2FPR2SCN9AADORA3
SCHEMBL15021019 0.92 FPR2 (0.46) PLATFPR2SCN9AADORA3ADORA2A
SCHEMBL15020570 0.92 FPR2 (0.42) PLATFPR2SCN9AADORA3ADORA2A
SCHEMBL15042227 0.92 FPR2 (0.46) PLATFPR2SCN9AADORA3ADORA2A
SCHEMBL15021003 0.90 PLAT (0.40) PLATKCNH2FPR2SCN9AADORA3
SCHEMBL15021004 0.90 PLAT (0.40) PLATKCNH2FPR2SCN9AADORA3
SCHEMBL15020575 0.89 PLAT (0.42) PLATFPR2SCN9AADORA3ADORA2A
SCHEMBL15020899 0.89 MAPT (0.48) KCNH2FPR2SCN9AMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 — — US claimed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 — — EP claimed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 — — US claimed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 — — US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 — — EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 PLAT 3840/4885KCNH2 2876/4885FPR2 2908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback